Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects
Condition: Human Influenza
MeSH terms: Influenza, Human
Intervention: Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)
Intervention description: A single 0.5 mL dose of study vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm.
Phase: Phase 2
Study type: Interventional
Primary purpose: Prevention
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 63.0
Sex: All
Minimum age: 65 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Influenza, Trivalent, Adjuvanted, Adjuvant, MF59, MF-59, Fluad, Seasonal

Summary:

      To evaluate the safety of a single intramuscular (IM) injection of trivalent adjuvanted
      influenza study vaccine, formulation 2012/2013, in elderly subjects and the antibody response
      to each influenza vaccine antigen, as measured by single radial hemolysis (SRH) and
      hemagglutination inhibition (HI) at approximately 21 days postimmunization in elderly
      subjects in compliance with the requirements of the current EU recommendations for clinical
      trials related to yearly licensing of influenza vaccines.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Male and female volunteers of 65 years of age or older, mentally competent, willing
             and able to give written informed consent prior to study entry;

          2. Individuals able to comply with all the study requirements;

          3. Individuals in good health as determined by the outcome of medical history, physical
             examination and clinical judgment of the investigator.

        Exclusion Criteria:

          1. Individuals with behavioral or cognitive impairment or psychiatric disease that, in
             the opinion of the investigator, could interfere with the subject's ability to
             participate in the study.

          2. Individuals with any serious chronic or acute disease (in the judgment of the
             investigator), including but not limited to:

               -  Medically significant cancer (except for benign or localized skin cancer, cancer
                  in remission for ≥10 years or localized prostate cancer that has been clinically
                  stable for more than 2 years without treatment);

               -  Medically significant advanced congestive heart failure (ie. NYHA class III and
                  IV);

               -  Chronic obstructive pulmonary disease (COPD; i.e., GOLD Stage III and IV);

               -  Autoimmune disease (including rheumatoid arthritis, except for Hashimoto's
                  thyroiditis that has been clinically stable for ≥ 5 years);

               -  Diabetes mellitus type I;

               -  Poorly controlled diabetes mellitus type II;

               -  Advanced arteriosclerotic disease;

               -  History of underlying medical condition such as major congenital abnormalities
                  requiring surgery, chronic treatment, or associated with developmental delay
                  (e.g., Down's syndrome);

               -  Acute or progressive hepatic disease;

               -  Acute or progressive renal disease;

               -  Severe neurological (es. Guillain-Barré syndrome) or psychiatric disorder;

               -  Severe asthma.

          3. Individuals with history of any anaphylactic reaction and/or serious allergic reaction
             following a vaccination, a proven hypersensitivity to any component of the study
             vaccine (e.g. to eggs or eggs product as well as ovalbumin, chicken protein, chicken
             feathers, influenza viral protein, kanamycin and neomycin sulphate).

          4. Individuals with known or suspected (or have a high risk of developing)
             impairment/alteration of immune function (excluding that normally associated with
             advanced age) resulting, for example, from:

               -  Receipt of immunosuppressive therapy (any parenteral or oral corticosteroid or
                  cancer chemotherapy/radiotherapy) within the past 60 days and for the full length
                  of the study;

               -  Receipt of immunostimulants;

               -  Receipt of parenteral immunoglobulin preparation, blood products and/or plasma
                  derivates within the past 3 months and for the full length of the study;

               -  Suspected or known HIV infection or HIV-related disease.

          5. Individuals with known or suspected history of drug or alcohol abuse.

          6. Individuals with a bleeding diathesis or conditions associated with prolonged bleeding
             time that in the investigator's opinion would interfere with the safety of the
             subject.

          7. Individuals who were not able to comprehend and to follow all required study
             procedures for the whole period of the study.

          8. Individuals with history or any illness that, in the opinion of the investigator, pose
             additional risk to the subjects due to participation in the study.

          9. Individuals who within the past 6 months have:

               -  had any laboratory confirmed seasonal or pandemic influenza disease;

               -  received any seasonal or pandemic influenza vaccine.

         10. Individuals who received any other vaccine within 4 weeks prior to enrollment in this
             study or who are planning to receive any vaccine during the study.

         11. Individuals with any acute or chronic infections requiring systemic antibiotic
             treatment or antiviral therapy within the last 7 days.

         12. Individuals that have experienced fever (i.e., axillary temperature ≥38°C) within the
             last 3 days of intended study vaccination.

         13. Individuals participating in any clinical trial with another investigational product 4
             weeks prior to first study visit or intent to participate in another clinical study at
             any time during the conduct of this study.

         14. Individuals who were part of study personnel or close family members conducting this
             study.

         15. BMI >35 kg/m2.